These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31853972)

  • 61. [Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].
    Pár A
    Orv Hetil; 2002 Dec; 143(48):2667-74. PubMed ID: 12501575
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predictive factors for adverse dermatological events during pegylated/interferon alpha and ribavirin treatment for hepatitis C.
    Li Z; Zhang Y; An J; Feng Y; Deng H; Xiao S; Ji F
    J Clin Virol; 2014 Jul; 60(3):190-5. PubMed ID: 24830933
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association between
    Yao Y; Liu M; Zang F; Yue M; Xia X; Feng Y; Fan H; Zhang Y; Huang P; Yu R
    BMJ Open; 2018 Apr; 8(4):e019406. PubMed ID: 29654010
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
    Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
    [No Abstract]   [Full Text] [Related]  

  • 65. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study.
    Liu CH; Huang YJ; Yang SS; Chang CH; Yang SS; Sun HY; Liu CJ; Liu WC; Su TH; Yang HC; Hong CM; Tseng TC; Chen PJ; Chen DS; Hung CC; Kao JH
    Sci Rep; 2018 Sep; 8(1):13699. PubMed ID: 30209349
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The influence of occult infection with hepatitis B virus on liver histology and response to interferon treatment in chronic hepatitis C patients.
    Silva Cd; Gonçales NS; Pereira JS; Escanhoela CA; Pavan MH; Gonçales FL
    Braz J Infect Dis; 2004 Dec; 8(6):431-9. PubMed ID: 15880234
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
    Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
    Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events.
    Butt AA; Yan P; Shuaib A; Abou-Samra AB; Shaikh OS; Freiberg MS
    Gastroenterology; 2019 Mar; 156(4):987-996.e8. PubMed ID: 30445009
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk of New-Onset Atrial Fibrillation Among Asian Chronic Hepatitis C Virus Carriers: A Nationwide Population-Based Cohort Study.
    Yang YH; Chiang HJ; Yip HK; Chen KJ; Chiang JY; Lee MS; Sung PH
    J Am Heart Assoc; 2019 Nov; 8(22):e012914. PubMed ID: 31711382
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The prevalence and clinical characteristics of coinfection of SENV-H among Taiwanese chronic hepatitis C patients with combination therapy of high-dose interferon-alfa and ribavirin.
    Dai CY; Chuang WL; Chang WY; Chen SC; Lee LP; Lin ZY; Hou NJ; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2004 Oct; 64(1):47-53. PubMed ID: 15451178
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
    Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
    Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice].
    Znoyko OO; Klimova EA; Maevskaya MV; Shuldyakov АA; Linkova YN; Morozova MA
    Ter Arkh; 2016; 88(11):156-162. PubMed ID: 28635836
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients.
    Farag RE; Arafa MM; El-Etreby S; Saudy NS; Eldeek BS; El-Alfy HA; Goda IF; Ali RM
    Arch Iran Med; 2013 Feb; 16(2):68-73. PubMed ID: 23360626
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
    Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan.
    Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
    J Chin Med Assoc; 2019 Sep; 82(9):693-698. PubMed ID: 31356562
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Isolation and functional analysis of circulating dendritic cells from hepatitis C virus (HCV) RNA-positive and HCV RNA-negative patients with chronic hepatitis C: role of antiviral therapy.
    Tsubouchi E; Akbar SM; Murakami H; Horiike N; Onji M
    Clin Exp Immunol; 2004 Aug; 137(2):417-23. PubMed ID: 15270861
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of direct-acting antiviral therapy.
    Wong GL; Chan HL; Loo CK; Hui YT; Fung JY; Cheung D; Chung C; Chim AM; Wong VW;
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1641-1647. PubMed ID: 30707777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.